In our study, Azeliragon treatment notably reduced these suppressive cell populations while increasing cytotoxic CD8+ T cell infiltration, thereby reshaping the immune environment towards a pro-inflammatory, anti-tumor state. Here, CD8A is linked to neoplasm.